Please use this identifier to cite or link to this item:
|Title:||Effect of Natural Polymorphisms in the HIV-1 CRF02_AG Protease on Protease Inhibitor Hypersusceptibility|
|Authors:||Santos, Andre F. A.|
Tebit, Denis M.
Lalonde, Matthew S.
Abecasis, Ana B.
Camacho, Ricardo J.
Diaz, Ricardo S. [UNIFESP]
Soares, Marcelo A.
Arts, Eric J.
Case Western Reserve Univ
Universidade Federal do Rio de Janeiro (UFRJ)
Hosp Egas Moniz
Universidade Federal de São Paulo (UNIFESP)
Inst Nacl Canc
|Publisher:||Amer Soc Microbiology|
|Citation:||Antimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 56, n. 5, p. 2719-2725, 2012.|
|Abstract:||Hypersusceptibility (HS) to inhibition by different antiretroviral drugs (ARVs) among diverse HIV-infected individuals may be a misnomer because clinical response to treatment is evaluated in relation to subtype B infections while drug susceptibility of the infecting virus, regardless of subtype, is compared to a subtype B HIV-1 laboratory strain (NL4-3 or IIIB). Mounting evidence suggests that HS to different ARVs may result in better treatment outcome just as drug resistance leads to treatment failure. We have identified key amino acid polymorphisms in the protease coding region of a non-B HIV-1 subtype linked to protease inhibitor HS, namely, 17E and 64M in CRF02_AG. These HS-linked polymorphisms were introduced in the BD6-15 CRF02_AG molecular clone and tested for inhibition using a panel of protease inhibitors. in general, suspected HS-linked polymorphisms did increase susceptibility to specific protease inhibitors such as amprenavir and atazanavir, but the combination of the 17E/64M polymorphisms showed greater HS. These two mutations were found at low frequencies but linked in a sequence database of over 700 protease sequences of CRF02_AG. in direct head-to-head virus competitions, CRF02_AG harboring the 17E/64M polymorphisms also had higher replicative fitness than did the 17E or the 64M polymorphism in the CFR02_AG clone. These findings suggest that subtype-specific, linked polymorphisms can result in hypersusceptibility to ARVs. Considering the potential benefit of HS to treatment outcome, screening for potential HS-linked polymorphisms as well as preexisting drug resistance mutations in treatment-naive patients may guide the choice of ARVs for the best treatment outcome.|
|Appears in Collections:||Em verificação - Geral|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.